WallStSmart

Evotec SE ADR (EVO)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 9280% more annual revenue ($67.38B vs $718.32M). MRK leads profitability with a 3.6% profit margin vs -25.2%. EVO appears more attractively valued with a PEG of 1.42. MRK earns a higher WallStSmart Score of 42/100 (D).

EVO

Hold

42

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.0Quality: 5.5
Piotroski: 5/9Altman Z: 0.38

MRK

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EVOUndervalued (+89.5%)

Margin of Safety

+89.5%

Fair Value

$33.26

Current Price

$1.32

$31.94 discount

UndervaluedFair: $33.26Overvalued
MRKSignificantly Overvalued (-56.0%)

Margin of Safety

-56.0%

Fair Value

$85.13

Current Price

$133.72

$48.59 premium

UndervaluedFair: $85.13Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVO1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$362.27B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

Areas to Watch

EVO4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$600.61M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-28.6%2/10

ROE of -28.6% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : EVO

The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : EVO

The primary concerns for EVO are Revenue Growth, EPS Growth, Market Cap.

Bear Case : MRK

The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

EVO profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

EVO carries more volatility with a beta of 1.31 — expect wider price swings.

MRK is growing revenue faster at 4.7% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

EVO scores higher overall (42/100 vs 42/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evotec SE ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?